^
    Back
    Association details:
    Biomarker:DNAJB1-PRKACA fusion
    Cancer:Hepatocellular Cancer
    Drug:DS89002333 (PRKACA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Biochem Biophys Res Commun
    Title:

    Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model

    Published date:
    07/07/2022
    Excerpt:
    DS89002333 showed potent PRKACA inhibitory activity and inhibited fusion protein-dependent cell growth both in vitro and in vivo. Furthermore, this compound showed anti-tumor activity in an FL-HCC patient-derived xenograft model expressing the DNAJB1-PRKACA fusion gene.
    DOI:
    10.1016/j.bbrc.2022.07.008